Category Archives: Immunology

Immunology

Parker Institute for Cancer Immunotherapy (PICI) Welcomes Weill Cornell Medicine to Cancer Research Consortium – Weill Cornell Medicine Newsroom

San Francisco and New York Dec. 13, 2023 The Parker Institute for Cancer Immunotherapy (PICI), the largest concentration of immuno-oncology (IO) expertise in the world, announced it has added Weill Cornell Medicine to its network of preeminent academic and medical research institutions at the forefront of the fight against cancer. Under the agreement, Weill Cornell Medicine, with new PICI Network researchers, will establish a PICI immuno-oncology research center in New York City.

Since its inception, PICI has distributed $260 million to member researchers to support scientific research at its member research institutions, with Weill Cornell Medicine as the latest addition to its PICI Network. Dr. Jedd Wolchok, the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, and Dr. Taha Merghoub, Meyer Cancer Center deputy director, will co-direct the new PICI immuno-oncology research center.

Funding for PICIs centers supports bold, scientific research while bridging academia and biotech. PICI funds groundbreaking research and incubates, launches, and invests in new biotech companies. Its key focus is developing breakthroughs and technologies that can be translated quickly into curative treatments for patients. The expansion of PICI on the East Coast represents a new phase for the institute, enabling the development of more therapeutic approaches and technologies for cancer patients.

We are proud to welcome Weill Cornell Medicine to the PICI Network under the leadership of Drs. Wolchok and Merghoub, who serve as center director and co-director, said Sean Parker, PICI founder and chairman, whose previous philanthropy includes a 2013 gift that established the Sean Parker Institute for the Voice at Weill Cornell Medicine. Dr. Wolchok is one of the most distinguished researchers in the world, and his impact on the field of immunology has been immeasurable. His deep understanding of PICIs uniquely ambitious and collaborative approach and true passion for innovative scientific research form an incredible foundation upon which to build transformative patient impact at Weill Cornell Medicine.

Weill Cornell Medicine scientists target some of the most formidable health challenges of the 21st century, including cancer. PICI funding at Weill Cornell Medicine will facilitate the recruitment of world-class cancer immunology researchers; enable high-risk, high-reward cancer research studies to be conducted; support the training and development of the next generation of elite cancer clinician-researchers; and contribute to health equity and community outreach programs in the New York area.

The collaborative nature of the PICI Network and flexible nature of funding is critical for rapid progress, Dr. Wolchok said. The PICI collaborative network has in the past decade helped facilitate advances in cancer research that I could not have imagined before. I am excited to continue my collaboration with PICI in my new role at Weill Cornell Medicine.

Dr. Wolchok has been involved with PICI since its early days, having formerly served as Center Director for the PICI Center at Memorial Sloan Kettering Cancer Center, where he leveraged PICI funding to build out a top immunology research facility, was the primary investigator on PICIs MAHLER clinical trial, and mentored nine PICI Early Career Researcher Awardees. His leadership philosophy of promoting deep collaboration and driving innovation fully aligns with PICIs mission and vision.

A geneticist by training with expertise in immuno-oncology, Dr. Merghoub has been a Parker member researcher since its inception. Together, Drs. Wolchok and Merghoub lead a laboratory that is dedicated to improving and developing new approaches to cancer treatment, especially those that target the immune system.

Listen to Dr. Wolchok elaborate on the mission of the newly formed PICI Center at Weill Cornell Medicine, on PICIs Podcast, From Bench to Fireside.

The Parker Institute for Cancer Immunotherapy (PICI) is radically changing how cancer research is done. Founded in 2016 through a $250 million gift from Silicon Valley entrepreneur and philanthropist Sean Parker, the San Francisco-based nonprofit is an unprecedented collaboration between the countrys leading immunotherapy researchers and cancer centers. PICI Network research institutions include Stanford Medicine; the University of California, Los Angeles; the University of California, San Francisco; the University of Pennsylvania; Dana-Farber Cancer Institute; Gladstone Institutes; and Weill Cornell Medicine. PICI also supports top researchers at other institutions, including The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, City of Hope, Fred Hutchinson Cancer Research Center, Icahn School of Medicine at Mount Sinai, Institute for Systems Biology and Washington University School of Medicine in St. Louis. By forging alliances with academic, industry and nonprofit partners, PICI makes big bets on bold research to fulfill its mission: to accelerate the development of breakthrough immunotherapies to turn all cancers into curable diseases. Find out more at parkerici.org and follow us on LinkedIn, X (formerly Twitter) @parkerici, and on Spotify.

Weill Cornell Medicine is committed to excellence in patient care, scientific discovery and the education of future physicians in New York City and around the world. The doctors and scientists of Weill Cornell Medicinefaculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and Weill Cornell Physician Organizationare engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies. Located in the heart of the Upper East Sides scientific corridor, Weill Cornell Medicines powerful network of collaborators extends to its parent university Cornell University; to Qatar, where Weill Cornell Medicine-Qatar offers a Cornell University medical degree; and to programs in Tanzania, Haiti, Brazil, Austria and Turkey. Weill Cornell Medicine faculty provide exemplary patient care at NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian Westchester Behavioral Health Center, NewYork-Presbyterian Lower Manhattan Hospital, NewYork-Presbyterian Queens and NewYork-Presbyterian Brooklyn Methodist Hospital. Weill Cornell Medicine is also affiliated with Houston Methodist. For more information, visitweill.cornell.edu.

More:
Parker Institute for Cancer Immunotherapy (PICI) Welcomes Weill Cornell Medicine to Cancer Research Consortium - Weill Cornell Medicine Newsroom

Immunology

Annals of Allergy, Asthma and Immunology Examines Effects of Climate Change on Allergic Conditions – Newswise

Newswise ARLINGTON HEIGHTS, Ill. (December 13, 2023) As we head into the new year, some issues may be coming into sharper focus for those involved in allergy-immunology issues. The current issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology, focuses its attention on a key problem affecting those with allergic conditions and the world today: climate change.

We recognize that climate change affects the global population, and that many people feel they as individuals dont have much control, says allergist Donald Leung, MD, PhD, Senior Executive Editor of Annals. But we also wanted to highlight the role of allergists in working with patients whose allergic diseases might be affected by global warming and climate change. There is evidence that the environment affects those living with asthma, seasonal allergic rhinoconjunctivitis, atopic dermatitis, and other allergic conditions. Our goal was to address the effects of climate change on those conditions through a series of well-researched articles by highly respected allergists.

The articles on this topic in the December issue are as follows:

These five articles highlight how climate change has affected diseases such as atopic dermatitis, asthma, allergic rhinitis and allergies in general. One example of the effect of climate change is that pollen seasons are lasting longer and starting earlier due to environmental warming. The CME review by Seastedt and Nadeau discusses how global fires and dust storms have increased atopic disease and worsened allergies. Global warming also has been shown to lead to disruption of the epithelial barrier, and as a result, alarmins can be induced, which leads to increasing T2 inflammation in allergy. An editorial by Dr. David Stukus stresses the important role that allergists can play in helping patients who are being affected by the effects of global warming and climate change.

About ACAAI

ACAAI is a professional medical organization of more than 6,000 allergists-immunologists and allied health professionals, headquartered in Arlington Heights, Ill. The College fosters a culture of collaboration and congeniality in which its members work together and with others toward the common goals of patient care, education, advocacy, and research. ACAAI allergists are board-certified physicians trained to diagnose allergies and asthma, administer immunotherapy, and provide patients with the best treatment outcomes. For more information and to find relief, visit AllergyandAsthmaRelief.org.Join us on Facebook, Pinterest, Instagram and Twitter/X.

See the original post here:
Annals of Allergy, Asthma and Immunology Examines Effects of Climate Change on Allergic Conditions - Newswise

Immunology

British Society for Immunology response to the NHS vaccination strategy – British Society for Immunology |

Today, NHS England has published the NHS vaccination strategy.

In response, the British Society for Immunology has released the following statement.

Dr Doug Brown, Chief Executive of the British Society for Immunology, said:

We are very pleased to see the release of the long-awaited NHS vaccination strategy today, which provides a much-needed opportunity to strengthen the impact of life-saving immunisation services to better protect our communities from preventable diseases. The British Society for Immunology has been calling for urgent action from the Government as England has continued to miss key targets on vaccination uptake, in particular following a 10-year decline in coverage of routine vaccinations for children. The new NHS vaccination strategy highlights key areas of work that we believe are crucial to ensure vaccination rates improve and can offer the best possible protection against serious preventable diseases, including increasing accessibility, boosting the outreach and partnerships with underserved communities, and creating a stronger more integrated system that uplifts the vaccination workforce. Vaccines are the safest and most effective method to protect our communities against disease. We must use the publication of this comprehensive strategy as the springboard to build on the lessons learnt from the COVID-19 vaccine rollout to facilitate better engagement with the public, particularly with those from underserved communities, about the importance of vaccination, both through widening community outreach and public health campaigns. While the ambitions laid out in this strategy are strong, their successful delivery will rely on the implementation of a strong leadership system and commissioning framework that are fit for function, alongside appropriate financing. We look forward to working with the NHS England and all partners involved to support the delivery of this strategy and further enable vaccines to play their vital role in improving the public health within our country.

---------ENDS---------- Notes for editors

You can read the full NHS vaccination strategy at: http://www.england.nhs.uk/long-read/nhs-vaccination-strategy.

You can download copies of the British Society for Immunologys guides to vaccinations, including for childhood vaccinations, vaccines for adults over 65 and COVID-19 vaccines here: http://www.immunology.org/public-information/vaccine-resources. The BSI guides are designed to answer common questions around how vaccinations work and why they are important.

For more information, please contact: Teresa Prados, Senior Communications Manager Tel: +44(0) 7464 621 014 Email: t.prados@immunology.org

Jennie Evans, Director of External Affairs Tel: +44(0) 7703 807 444 Email: j.evans@immunology.org

The British Society for Immunology is the UK organisation representing scientists and clinicians who study the immune system.

View post:
British Society for Immunology response to the NHS vaccination strategy - British Society for Immunology |

Immunology

NYU Langone Health in the NewsFriday, December 8, 2023 – NYU Langone Health

News from NYU Langone Health

NYS Health Department Says Flu Is Now Widespread in New York FOX 5 New York December 7 -Purvi S. Parikh, MD, clinical assistant professor, Department of Pediatrics, Division of Pediatric Allergy & Immunology, and Department of Medicine, Division of Infectious Diseases, Allergy and Immunology

A Guide to Flu Season, the Shot, Your Symptoms and How Long it Lasts Wall Street Journal December 7 -Purvi S. Parikh, MD, clinical assistant professor, Department of Pediatrics, Division of Pediatric Allergy & Immunology, and Department of Medicine, Division of Infectious Diseases, Allergy and Immunology

Your Health Information Was Hacked. What Now? (Subscription required or access is ProQuest.) The New York Times December 7 -Eduardo Iturrate, MD, associate professor, Department of Medicine, NYU Grossman School of Medicine

Podcast: Is Xenotransplantation Ready for Prime Time? New England Journal of Medicine December 7 -Robert Montgomery, MD, DPhil, the H. Leon Pachter, MD, Professor of Surgery, chair, Department of Surgery, Division of Transplant Surgery, NYU Langone Transplant Institute

Compelling Case for Skipping RT in Some Early Breast Cancers (Free log-in required.) Medscape December 7 -Naamit K. Gerber, MD, associate professor, Department of Radiation Oncology, Perlmutter Cancer Center

Rheumatoid Arthritis Drug Shows Promise as Type 1 Diabetes Treatment Medical News Today December 7 -Eliud Sifonte, MD, clinical assistant professor, Department of Medicine, Division of Endocrinology

Women With Late-Stage Estrogen-Fueled Breast Cancer on the Cusp of More Treatment Options Possibly Enhancing Quality of Life SurvivorNet December 7 -Sylvia Adams, MD, professor, Department of Medicine, Division of Hematology and Medical Oncology, director, Breast Cancer Center, Perlmutter Cancer Center

Old Disease, New Tricks: A Novel Approach to Understanding Gout The Rheumatologist December 7 -Michael H. Pillinger, MD, professor, Department of Medicine, Division of Rheumatology, and Department of Biochemistry and Molecular Pharmacology

Allergist, Dermatologist, or Immunologist? Meet Your CSU Care Team HealthCentral December 7 -Purvi S. Parikh, MD, clinical assistant professor, Department of Pediatrics, Division of Pediatric Allergy & Immunology, and Department of Medicine, Division of Infectious Diseases, Allergy and Immunology

How to Cope When Psoriatic Arthritis Affects Your Feet HealthCentral December 7 -NYU Langone Health

What Are the Symptoms of MS in Women? HealthCentral December 7 -Tyler E. Smith, MD, clinical assistant professor, Department of Neurology

This Is How Fast You Should Walk to Lower Your Diabetes Risk, According to a New Study Verywell Health December 7 -Priya Jaisinghani, MD, clinical assistant professor, Department of Medicine, Division of Endocrinology, Diabetes and Metabolism

COVID Vaccination Rates Alarmingly Low Among Nursing Home Staff, CDC Says: A Real Danger FOX News December 7 -Marc K. Siegel, MD, clinical professor, Department of Medicine, Division of General Internal Medicine

Art Caplan Discusses 23AndMe Data Breach and Purdue Pharma Settlement Boston Public Radio December 6 -Arthur L. Caplan, PhD, the Drs. William F. and Virginia Connolly Mitty Professor, Department of Population Health, Division of Medical Ethics

NYU Langone to Contribute to Village Sewer Upgrade Garden City News December 7 -NYU Langone Health

Health Departments Warn Schools Not to Accept Vaccination Cards from Julie DeVuono, Wild Child Pediatrics (Subscription required.) Newsday December 7 -Leonard R. Krilov, MD, professor, Department of Pediatrics, chair of pediatrics, NYU Langone HospitalLong Island

NYU Langones Family Support Center Is Awarded $50K for Food Distribution Program Brooklyn Eagle December 7 -Larry K. Mcreynolds, clinical associate professor, Department of Population Health, Family Health Centers, executive director

Read the original:
NYU Langone Health in the NewsFriday, December 8, 2023 - NYU Langone Health

Immunology

Arturo Casadevall Named Distinguished Fellow by the American Association of Immunologists – Johns Hopkins Bloomberg School of Public Health

Arturo Casadevall, MD, PhD,Bloomberg Distinguished Professor, and Alfred and Jill Sommer Professor and Chair of the Department of Molecular Microbiology and Immunology at the Bloomberg School, has been named a 2024 Distinguished Fellow by the American Association of Immunologists (AAI). Congratulations, Arturo!

The Fellows program recognizes members for distinguished careers and outstanding scientific contributions, as well as their service to AAI and the immunology community. It honors active, long-term members (25 years or more) who have demonstrated one or more of the following: significant research accomplishment in the field of immunology; exceptional leadership to the immunology community in academia, foundations, nonprofits, industry, or government, at a national or international level; and/or distinction in education and teaching.

Election as a Distinguished Fellow by the AAI Council is among the highest honors bestowed by AAI.

The American Association of Immunologists is an association of professionally trained scientists from all over the world dedicated to advancing the knowledge of immunology and its related disciplines, fostering the interchange of ideas and information among investigators, and addressing the potential integration of immunologic principles into clinical practice. AAI owns and publishesThe Journal of Immunology, the largest and most highly cited journal in the field.

Original post:
Arturo Casadevall Named Distinguished Fellow by the American Association of Immunologists - Johns Hopkins Bloomberg School of Public Health

Immunology

ImmunoScape Appoints Systems Immunology and Computational Biology Expert Dr. John Tsang to its Scien – PharmiWeb.com

Expertise from award-winning computational biologist, human immunologist and engineer with experience from Yale, NIH, and NIAID will help advance ImmunoScapes machine learning capabilities

SAN DIEGO & SINGAPORE--(BUSINESS WIRE)--ImmunoScape, a biotechnology company focused on next-generation immunotherapies, today announced the appointment of John Tsang, Ph.D. to its Scientific Advisory Board (SAB). Dr. Tsang joins a distinguished group of leading scientists in immunology and oncology who help to guide ImmunoScapes scientific strategy.

Dr. Tsang is currently Professor of Immunobiology and Biomedical Engineering at Yale University. He is the founding Director of the Yale Center for Systems and Engineering Immunology (CSEI), which serves as a home and cross-departmental center of research for systems, quantitative, and synthetic immunology at Yale. He is also the Yale lead and Executive Committee member of the recently announced Chan Zuckerberg Biohub New York, a landmark collaboration between Columbia, Rockefeller, and Yale Universities with long-term support from the Chan Zuckerberg Initiative to bioengineer immune cells for early disease detection and prevention. Prior to joining Yale, he was a tenured Senior Investigator in the National Institutes of Health's Intramural Research Program and led a laboratory focusing on systems and quantitative immunology at the National Institute of Allergy and Infectious Diseases (NIAID) where he remains an Adjunct Investigator. Dr. Tsang was also the Co-Director of the Trans-NIH Center for Human Immunology (CHI) and led its research program in systems human immunology.

Our team is thrilled that he has joined our Scientific Advisory Board, as his deep expertise across immunology and computational and systems biology will be invaluable as we continue to push the machine learning capabilities of our platform forward, said Choon-Peng Ng, co-founder and CEO, ImmunoScape. Alongside the other distinguished advisory board members, Dr. Tsang will be able to directly advise our computational biology leaders, provide unique research perspectives, and guide our strategic scientific and technological direction.

Dr. Tsangs expertise directly aligns with ImmunoScapes goal to utilize its machine learning capabilities to build its TCR discovery pipeline as the company extends into the oncology field. ImmunoScapes discovery engine offers 360-degree views of lab-validated data from millions of T cells, which serves as the foundation for its machine learning platform. By identifying the characteristics of tumor-reactive TCRs across hundreds of solid tumor targets and multiple HLA alleles, ImmunoScape aims to leverage deep T-cell profiles, linking TCR sequence, phenotypes and antigen information to unlock the faster discovery of novel and efficacious TCR-based therapies across a variety of tumor indications. These capabilities were recently highlighted in new peer-reviewed research ImmunoScape published in Cell Reports.

Dr. Tsang has won multiple awards for his research, including several NIH/NIAID Merit Awards recognizing his scientific leadership in systems immunology, COVID-19, and human immunology research. His work on human immune variability, systems immunology, and prediction of vaccination responses was selected as a Top NIAID Research Advance of 2014. Tsang has served as an advisor on systems immunology and computational biology for numerous programs and organizations, including the Allen Institute, World Allergy Organization, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, and the Fred Hutchinson Cancer Center. Dr. Tsang earned his Ph.D. in biophysics and systems biology from Harvard University and trained in computer engineering (BASc) and computer science (MMath) at the University of Waterloo, Canada.

I am inspired by ImmunoScapes mission to harness the power of machine learning and deep immune profiling to accelerate discovery and eventually expand access to more effective therapeutics for cancer, said Dr. John Tsang. I look forward to working closely with the team to further advance their powerful machine learning and discovery platform that could help transform the development of more effective, novel therapeutics for solid tumors.

The other members of the ImmunoScape SAB include Evan Newell, Ph.D., (chairman), Philip Greenberg, M.D., Paul Thomas, Ph.D., Patrick Reeves, Ph.D., Rachel Humphrey, M.D., and Adrian Woolfson, Ph.D.

To learn more about ImmunoScape, please visit https://immunoscape.com/.

About ImmunoScape ImmunoScape is a biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company's proprietary Deep Immunomics technology and machine learning platforms enable highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. For more information, please visit https://immunoscape.com/.

Kalyn Kolek for ImmunoScape kos@anzupartners.com

Read more from the original source:
ImmunoScape Appoints Systems Immunology and Computational Biology Expert Dr. John Tsang to its Scien - PharmiWeb.com

Immunology

Ishares Genomics Immunology And Healthcare Etf ($IDNA) Proactive Strategies – Stock Traders Daily

December 13, 2023, 23:00 pm ET, BY David D.- Contributor| Editor: Thomas H. Kee Jr. (Follow on LinkedIn)

The technical summary data tells us to buy IDNA near 21.45, but there is no current upside target from the summary table. In this case we should wait until either an update to the summary table has been made (which usually happens at the beginning of every trading day), or until the position has been stopped. The data does tell us to set a stop loss 21.39 to protect against excessive loss in case the stock begins to move against the trade. 21.45 is the first level of support below 22, and by rule, any test of support is a buy signal. In this case, if support 21.45 is being tested, a buy signal would exist.

NONE . There are no current resistance levels from the summary table, and therefore there are no Short resistance Plans which tell us to short upon tests of resistance. Resistance levels have broken higher and unless the stock reverses lower and below support levels again short positions look risky.

If n/a begins to break higher, the technical summary data tells us to buy IDNA just slightly over n/a, with an upside target of n/a. The data also tells us to set a stop loss @ 0 in case the stock turns against the trade. n/a is the first level of resistance above 22, and by rule, any break above resistance is a buy signal. In this case, n/a, initial resistance, would be breaking higher, so a buy signal would exist. Because this plan is based on a break of resistance, it is referred to as a Long Resistance Plan.

The technical summary data is suggesting a short of IDNA if it tests n/a with a downside target of 21.49. We should have a stop loss in place at 0 though in case the stock begins to move against the trade. By rule, any test of resistance is a short signal. In this case, if resistance, n/a, is being tested a short signal would exist. Because this plan is a short plan based on a test of resistance it is referred to as a Short Resistance Plan.

If n/a begins to break higher, the technical summary data tells us to buy IDNA just slightly over n/a, with an upside target of n/a. The data also tells us to set a stop loss @ 0 in case the stock turns against the trade. n/a is the first level of resistance above 22, and by rule, any break above resistance is a buy signal. In this case, n/a, initial resistance, would be breaking higher, so a buy signal would exist. Because this plan is based on a break of resistance, it is referred to as a Long Resistance Plan.

The technical summary data is suggesting a short of IDNA if it tests n/a with a downside target of 21.49. We should have a stop loss in place at 0 though in case the stock begins to move against the trade. By rule, any test of resistance is a short signal. In this case, if resistance, n/a, is being tested a short signal would exist. Because this plan is a short plan based on a test of resistance it is referred to as a Short Resistance Plan.

This is a snapshot. Real Time Updates are available on our IDNA Page.

IDNA Ratings for December 13:

Blue = Current Price Red= Resistance Green = Support

Click the Get Real Time Updates button below.

In the login prompt, select forgot username

Type the email you use for Factset

Use the user/pass you receive to login

You will have 24/7 access to real time updates.

From then on you can just click to get the real time update whenever you want.

GET REAL TIME UPDATES

Evitar Corte warned of market crash risk four times since 2000.

It identified the Internet Debacle before it happened.

It identified the Credit Crisis before it happened.

It identified the Corona Crash too.

See what Evitar Corte is Saying Now.

Get Notified When our Ratings Change:Take a Trial

Don't over think it! TradingIshares Genomics Immunology And Healthcare Etf(NASDAQ: IDNA) or any other stock can be rewarding if the simple rules of technical analysis are observed before making any decisions. This should be an integral part of the investment process.

Subscribers also receive market analysis, stock correlation tools, macroeconomic observations, timing tools, and protection from market crashes using Evitar Corte.

Fundamental Charts for IDNA:

Follow this link:
Ishares Genomics Immunology And Healthcare Etf ($IDNA) Proactive Strategies - Stock Traders Daily

Immunology

Medical Breakthroughs Fueling Infection Prevention Market: Immunology and Modern Medicine Advancements to … – PR Newswire

A new report from FMI highlights key factors propelling the growth of the infection prevention market. The report identifies rising surgical procedures, environmental sustainability trends, the development of biodegradable solutions, and growing awareness of health and hygiene as major drivers of market expansion.

NEWARK, Del., Dec. 12, 2023 /PRNewswire/ -- The global infection prevention market is estimated to be over US$ 40,845.2 million in 2024. Between 2024 and 2034, the market is predicted to grow at 3.1%, reaching a valuation of US$ 55,379.1 million by that year. The infection prevention and control market is expanding globally due to rising outsourcing efforts, healthcare spending, impressive healthcare standards, and infrastructural advances.

Request Exclusive Sample Report: Infection Prevention Market Strategic Insights: https://www.futuremarketinsights.com/reports/sample/rep-gb-13950

The number of surgical operations performed globally has increased. This is due to a rise in the frequency of lifestyle illnesses, increased obesity, and other factors. Aside from that, numerous athletes suffer from severe injuries, including spinal injuries and elbow injuries. As a result, many operations have increased the need for infection prevention kits.

Growing public consciousness of environmental sustainability opens up lucrative growth opportunities for the industry. Biodegradable gloves, eco-friendly packaging, and environmentally friendly production methods are just a few of the environmentally friendly and recyclable infection control items that are becoming increasingly popular. Manufacturers are trying to reduce the amount of garbage they produce and their carbon footprints.

Biodegradable infection control solutions from plant-based polymers derived from sustainable resources such as cornstarch, sugarcane, or cellulose are becoming increasingly popular. These polymers can create gloves, aprons, packing materials, and disposable gowns. Eco-friendly and biodegradable infection control solutions have propelled market expansion.

The growth in infection incidence indicates an increasing global need for efforts to address the underlying cause of sickness and reduce the risk of transmission. Revenues from reimbursement are expected because of the growing demand for consumables, disinfectants, and sterilizing equipment in the healthcare sector.

Customers are expected to demand infection-prevention products as they become more conscious of their hygiene and health. The aging population's growing desire for better healthcare is predicted to result in increasing sales potential.

Infection Prevention Industry Overview, 2024-2034:

Attributes

Infection Prevention Market

CAGR (2024 to 2034)

3.1%

Expected Base Year Value (2024)

US$ 40,845.2 million

Anticipated Forecast Value (2034)

US$ 55,379.1 million

Growth Factors

Growing prevalence of chronic disorders all over the world.

Future Opportunities

Key Companies profiled

Understand global, regional, and country-level parameters with growth opportunities, historical data (2019-2023), and forecasts (2024-2034).Buy this report today!

Sabyasachi Ghosh(Associate Vice President at Future Market Insights, Inc.), States, "The main factor driving the market is the growing demands for efficient cleaning and awareness of the need to clean and disinfect the environment. Furthermore, the market for infection prevention is poised for significant expansion because of the coronavirus outbreak."

Key Takeaways from the Infection Prevention Market:

Key Strategies:

The global infection control market is highly competitive, with several companies participating. Market rivalry is fierce, with businesses contending for customers' attention by introducing new, high-quality products. Infection control is a highly competitive sector with many small and medium-sized establishments.

These businesses often focus on specific service or product categories within a given market. Many industry participants focus on organic market expansion through product debuts, approvals, and other variables such as patents and events. The inorganic growth tactics were partnerships, acquisitions, and collaborations.

Recent Developments:

About Healthcare Division at Future Market Insights (FMI)

Future Market Insights (FMI) facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you to devise innovation-driven trajectories for your business. Know more about our sector coverage here.

About the Author:

Sabyasachi Ghosh(Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges clients faces and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

Explore FMI's Extensive Coverage in the Healthcare Domain:

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading market intelligence and consulting service provider, serving clients in over 150 countries. FMI is headquartered inDubaiand has delivery centers in theUnited Kingdom,the United States, andIndia. FMI's latest market research reports, and industry analysis helps businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition.

Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us

Nandini Singh Sawlani Future Market Insights Inc. Christiana Corporate, 200 Continental Drive, Suite 401,Newark, Delaware- 19713,USA T: +1-845-579-5705 For Sales Enquiries:[emailprotected] Website:https://www.futuremarketinsights.com LinkedIn|Twitter|Blogs|YouTube

Logo: https://mma.prnewswire.com/media/1197648/3531122/FMI_Logo.jpg

SOURCE Future Market Insights

See the article here:
Medical Breakthroughs Fueling Infection Prevention Market: Immunology and Modern Medicine Advancements to ... - PR Newswire

Immunology

Cancer therapy bexmarilimab awakens immune cells to attack tumors that have avoided the detection of the immune … – EurekAlert

image:

The image shows cancer cells and macrophage immune cells. The macrophages are depicted in red whereas the cancer cells are the white-grey spots. The nuclei are shown in blue.

Credit: Jenna Rannikko

Researchers at the University of Turku, Finland, have uncovered how the new bexmarilimab therapy alters the function of immune cells so that they can infiltrate the tumor in cancer patients who do not respond to any other current therapies.

Cancer immunotherapy utilizes the bodys own defense machinery, the immune system, to fight against cancer. Novel immunotherapies are being developed to help patients whose immune cells fail to attack cancer even with the aid of currently available therapies.

One potential future cancer therapy, bexmarilimab, changes macrophage behavior to promote anti-tumor immune defense. Macrophages are highly plastic immune cells that cancer can utilize to avoid detection by the immune system. Principal Investigator Maija Hollmns research group at the InFLAMES Research Flagship at the University of Turku in Finland has investigated how bexmarilimab therapy alters immune cell function within patient tumors.

In a clinical trial for advanced-stage cancer, bexmarilimab therapy was well tolerated and stabilized disease progression in subsets of patients. In patients benefitting from the therapy, we observed tumor-associated macrophage and lymphocyte activation as well as induction of interferons, which are all important signs of anti-tumoral immune defense, says Dr Hollmn.

The study utilized a novel spatial transcriptomics method that allowed the researchers to investigate changes in immune cell gene expression in a spatial context of patient tissue samples.

Efficacy in tumors resistant to current immunotherapies

Individual cancer patients differ greatly in their sensitivity to immunotherapies, as tumors can resist immune attacks to varying degrees. Therefore, its important to identify tumor types where a novel immunotherapy has highest efficacy.

By treating patient-derived cancer cells and immune cells with bexmarilimab in cell cultures, Hollmns group could study in detail how individual immune cells react to bexmarilimab.

We observed similar immune system activation in patient-derived cell cultures as we saw within patient tumors: bexmarilimab stimulates the macrophages, which can then activate T lymphocytes that are proficient in killing cancer cells. Successful treatment therefore depends on the co-operation of several immune cell types, describes Jenna Rannikko, who is the first author of the related research articles.

The similarities between the clinical study and patient-derived cell cultures encouraged the group to investigate why bexmarilimab lacks efficacy in some patients. They discovered that macrophage exposure to interferons prevents bexmarilimab from activating them.

This is highly significant, as it means that bexmarilimab would be most efficacious in tumors where currently available immunotherapies work poorly. Those tumors have lower levels of interferons. After bexmarilimab-induced anti-tumoral immunity, these tumors could become sensitive to currently available immunotherapies as well, concludes Rannikko.

Bexmarilimab is a new cancer drug developed by Faron Pharmaceuticals in Turku, Finland. The research was published in the esteemed peer-reviewed journals Cell Reports Medicine and Cancer Immunology Research in November and December 2023.

Cell Reports Medicine

Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial

5-Dec-2023

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See the original post:
Cancer therapy bexmarilimab awakens immune cells to attack tumors that have avoided the detection of the immune ... - EurekAlert

Immunology

Testing Cancer Immunotherapies on Mice with Human Immune Systems – Mirage News

Mice with human immune cells are a new way of testing anti-cancer drugs targeting the immune system in pre-clinical studies. Using their new model, the Kobe University research team successfully tested a new therapeutic approach that blindfolds immune cells to the body's self-recognition system and so makes them attack tumor cells.

Cancer cells display structures on their surface that identify them as part of the self and thus prevent them from being ingested by macrophages, a type of immune cell. Cancer immunotherapy aims at disrupting these recognition systems. Previous studies showed that a substance that blinds macrophages to one of these identifiers, called "CD47," by disabling their CD47-scanning structure, "SIRP," can activate the cells to fight the tumor when given in combination with therapeutic cancer-targeting antibodies such as Rituximab. However, because this approach is so specific to the self-identification of human cells, until now it could only be tested in humans or monkeys, making pre-clinical studies in mice impossible.

To overcome this, Kobe University immuno-oncologist SAITO Yasuyuki and his team built on their experience with creating mouse immunological models and transplanted parts of the human immune system into mice. Saito says, "Studies using mouse models with humanized immune systems have focused on lymphocytes, a type of immune cell relevant to infectious diseases.

The special aspect of our approach is that our new mouse model focuses on macrophages because we want to target them for the development of new cancer immunotherapies." This enabled the researchers to both create a more fully functioning mouse model of human cancer and test the effectiveness of the blindfolding approach for the first time in this environment.

Their results, published in the journal Frontiers in Immunology, showed that the macrophage-targeted therapy indeed induced an effective cancer response. However, Saito explains, "The most exciting aspect of this result is that this approach not only promotes the engulfment (ingestion) of tumor cells by macrophages but also reprograms tumor-associated macrophages, one of the current topics of cancer immunotherapy."

The immune system has an ambiguous role in the development of and fight against cancer. On the one hand, it can recognize cancer cells and fight them. On the other hand, macrophages also associate with tumors, both supporting their growth and suppressing other anti-tumor immune responses. To turn these cells against cancer is the novel approach that the Kobe University researchers could now help propel forward with their new humanized mouse model.

But the result has a broader relevance, too. Saito says, "There were no suitable preclinical in vivo models to develop therapeutics targeting human macrophages surrounding tumors, so new approaches had to be tested directly on patients. I believe our model perfectly fills the gap and may help in the selection of the most effective treatment from several candidates for therapeutics targeting human immune cells. The long-term goal of my project is to develop a humanized immune system mouse model that faithfully represents the immune response against the tumor."

This study was supported by the Ministry of Education, Culture, Sports, Science, and Technology of Japan Grant-in-Aids 20K21547, 21H04807 and 20K16358; by Japan Agency for Medical Research and Development (AMED) grants 21cm0106308h0006 and 22674074; by Japan Science and Technology Agency (JST) grant JPMJPF2018; by the Bristol-Myers Squibb Foundation, the Takeda Science Foundation, and by the Japanese Society of Hematology. It was conducted in collaboration with researchers from the University and University Hospital Zurich and the Comprehensive Cancer Center Zurich.

Kobe University is a national university with roots dating back to the Kobe Commercial School founded in 1902. It is now one of Japan's leading comprehensive research universities with nearly 16,000 students and nearly 1,700 faculty in 10 faculties and schools and 15 graduate schools. Combining the social and natural sciences to cultivate leaders with an interdisciplinary perspective, Kobe University creates knowledge and fosters innovation to address society's challenges.

Go here to read the rest:
Testing Cancer Immunotherapies on Mice with Human Immune Systems - Mirage News